Back to News
Market Impact: 0.3
Orbis Medicines Partners With Novo In Up To $1.4 Billion Drug Discovery Deal
Source: Nasdaq
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Privately held Orbis Medicines entered a strategic collaboration and licensing agreement with Novo Nordisk to discover and develop next-generation oral therapies for cardiometabolic diseases, including obesity and related metabolic disorders. The partnership expands Novo Nordisk's pipeline efforts in a high-growth obesity-treatment market, though financial terms and development timelines were not disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
NVO0.55
More News
- Anthropic quietly sets up biology lab as it ramps AI drug program: Reuters
- Anthropic is operating a lab that conducts biology experiments
- UBS now expects AI capex to reach nearly $1tn this year and around $1.4tn by 2027
- Warren Buffett stepping down as chairman of Berkshire Hathaway: 'Father Time always wins'
- Japan has record 100,000 people aged over 100: How societies are ageing
- Flock Offers Employees Buyouts as Customers Flee